tirzepatide weight loss surmount-1 results percent weight loss 72 weeks reduction over time in tirzepatide‐treated participants by early response: Post hoc analysis in SURMOUNT‐1 - Ard - 2025 - Diabetes, Obesity and Metabolism Tirzepatide vs semaglutide: A new

The commercial case for biosimilar switching strengthens in a post-IRA pricing environment where every line-item biologic expenditure is scrutinized

In patients without diabetes, tirzepatide provided an additional 3.6% weight loss compared to semaglutide, while in patients with diabetes, the percentage change in body weight was not statistically different between the two groups

Comparing the peptide approach to weight loss with stimulant-based approaches reveals fundamentally different philosophies: peptides work with your body biology to change hunger signaling and metabolic patterns, while stimulants override fatigue signals without addressing underlying causes

While Mounjaro (tirzepatide) was originally approved for Type 2 diabetes, Zepbound (tirzepatide) is FDA-approved specifically for chronic weight management in adults with obesity (BMI 30 or above) or overweight (BMI 27 or above) with at least one weight-related condition such as hypertension, high cholesterol, or sleep apnea

Plaintiffs claim manufacturers: Knew or should have known gastroparesis could be permanent Failed to adequately warn patients and doctors Understated the severity and duration of risk Continued aggressive marketing despite safety signals 2